Your session is about to expire
← Back to Search
Atezolizumab +/− Selinexor for Sarcoma
Study Summary
This trial is testing whether atezolizumab, either alone or combined with selinexor, is better than the current standard of care for alveolar soft part sarcoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had mild or moderate infection symptoms within the last 2 weeks.I have had treatment for any painful cancer spots before joining.I frequently need procedures to remove excess fluid from my chest or abdomen.I have had leptomeningeal disease.I haven't had chemotherapy or radiotherapy in the last 4 to 6 weeks.I have not had major surgery in the last 28 days.I have had cancer other than ASPS before.I haven't taken any immune-boosting drugs in the last 4 weeks or 5 half-lives of the drug.I have a history of cancer.I have pain from my cancer that isn't relieved by treatment.My kidney function, measured by creatinine levels or clearance, is within the required range.I haven't taken any cancer treatments within the last 4 weeks or five half-lives, whichever is shorter.I have received a COVID-19 vaccine.I haven't taken any immune-weakening drugs in the last 2 weeks and don't expect to need any during the study.I have a significant liver condition.I have a serious heart condition.I don't have any health issues that prevent me from taking new medications.I am currently on medication for hepatitis B.I can and am willing to take pills.I understand selinexor or atezolizumab may harm my pregnancy.I haven't had cancer in the last 5 years, except for skin cancer.I have had a condition where my lymphocytes grow abnormally.I am HIV positive, on treatment, and my viral load is undetectable.I do not have any health conditions that would prevent me from taking a new drug.I have an advanced soft tissue sarcoma.My cancer is a type called alveolar soft part sarcoma and cannot be removed by surgery.My ASPS is spreading and cannot be removed via surgery.I have active tuberculosis.I have not received a live vaccine in the last 4 weeks.I am mostly self-sufficient and can carry out daily activities.I am willing to give samples for research.I haven't taken any experimental drugs within the last 28 days.I had hepatitis B in the past but it's resolved now.I have high calcium levels in my blood that are causing symptoms.I am 18 years old or older.I do not have conditions affecting my body's ability to absorb nutrients.I do not have a brain tumor or symptoms from cancer spread to my brain, with some exceptions.
- Group 1: Arm II (atezolizumab)
- Group 2: Arm I (atezolizumab, selienexor)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper limit of participants taking part in this experiment?
"Affirmative. Clinicaltrials.gov documents demonstrate that this research study is actively seeking volunteers, having first been announced on April 21st 2022 and most recently updated November 8th 2022. A total of 77 individuals are required from 3 different medical sites to complete the trial."
Is this experiment presently seeking participants?
"According to the information provided on clinicaltrials.gov, this trial is actively searching for suitable candidates. The study was initially advertised on April 21st 2022 and has been recently refreshed as of November 8th 2022."
Has Atezolizumab been officially authorized by the FDA?
"The safety of Atezolizumab has been determined to be a 2 by the team at Power, as there is some evidence that attests its security but no data confirming its efficacy."
Share this study with friends
Copy Link
Messenger